Test Bank Pharmacotherapeutics for Advanced Practice Nurse Prescribers 6e Teri Moser Woo
n n n n n n n n n n n
Woo 1
Pharmacotherapeutics nfornAPNnPrescribers, n6e Ch01
Chapter n1.nThenRolenofnthenAdvancednPractice nNurse nasnPrescriber
MULTIPLEnCHOICE
1. Nursen practitionern prescriptiven authorityn isn regulated n by:
A. Then Nationaln Counciln of n Staten Boardsn of n Nursing
B. Then U.S.n Drugn Enforcement n Administration
C. Then Staten Board n of n Nursingn forn eachn state
D. Then Staten Board n of n Pharmacy
ANS:n C PTS:n n 1
2. Then benefitsn ton thenpatient nofnhavingn annadvanced npracticen registered n nursen (APRN)n prescribern i
nclude:
A. Nursesn know n moren about n pharmacologyn thannothern prescribersn becausen theyn taken it n
bothn inn theirn basicn nursingn programn and n inn theirn APRN n program.
B. Nursesn caren forn then patient nfromn anholisticn approachn andnincludenthenpatient ninnd
ecision-makingn regardingn theirn care.
C. APRNsn aren lessn likelyn ton prescriben narcoticsn and n othern controlled n substances.
D. APRNsn aren ablen tonprescriben independentlyn inn alln states,n whereasn an physician’sn
assistant n needsn ton haven an physiciann supervisingn theirn practice.
ANS:n B PTS:n n 1
3. Clinicaln judgment n inn prescribingn includes:
A. Factoringn inn then cost n ton then patient n of n then medicationn prescribed
B. Alwaysn prescribingn then newest n medicationn availablen forn then diseasen process
C. Handingn out n drugn samplesn ton poorn patients
D. Prescribingn alln genericn medicationsn ton cut n costs
ANS:n A PTS:n n 1
4. Then processn forn choosingn ann effectiven drugn forn an disordern includes:
A. Askingn then patient n what n drugn theyn thinkn would n workn best n forn them
B. Consultingn nationallyn recognized n guidelinesn forn diseasen management
C. Prescribingn medicationsn that n aren availablen asn samplesn beforen writingn an prescription
D. Followingn U.S.n Drugn Enforcement n Administrationn guidelinesn forn prescribing
ANS:n B PTS:n n 1
5. Nonintentionaln nonadherencen of n drugn therapyn mayn occurn duen to:
A. Belief n that n medicationn doesn not n work
B. Adversen drugn reactions
C. Chronicn conditionsn that n requiren dailyn therapy
D. Forgetfulnessn orn distraction
ANS:n D PTS:n n 1
, Woo 1
PharmacotherapeuticsnfornAPNnPrescribers,n6e Ch02
Chapter n2.nReviewnofnBasic nPrinciples nofnPharmacology
MULTIPLEnCHOICE
1. A n patient’sn nutritionaln intaken andn laboratoryn resultsn reflect n hypoalbuminemia.n Thisn isn criticaln t
on prescribingn because:
A. Distributionn of n drugsn ton target n tissuen mayn ben affected.
B. Then solubilityn of n then drugn willn not n matchn then siten of n absorption.
C. Theren willn ben lessn freen drugn availablen ton generaten ann effect.
D. Drugsn bound n ton albuminn aren readilyn excreted n byn then kidneys.
ANS:n A PTS:n n 1
2. Drugsn that n haven an significant n first-passn effect:
A. Must n ben givenn byn then enteraln (oral)n routen only
B. Bypassn then hepaticn circulation
C. Aren rapidlyn metabolized n byn then livern and n mayn haven little,n if n any,n desired n action
D. Aren converted n byn then livern ton moren activen and n fat-solublen forms
ANS:n C PTS:n n 1
3. Then routen of n excretionn of n an volatilen drugn willn likelyn ben the:
A. Kidneys
B. Lungs
C. Bilen and n feces
D. Skin
ANS:n B PTS:n n 1
4. A n majorn disadvantagen ton IV n administrationn isn that:
A. First-passn metabolismn isn eliminated.
B. Needlesn and n sterilityn aren required.
C. Absorptionn of n then drugn cannot n ben slowed n aftern administration.
D. It n isn significantlyn moren expensiven thann othern routes.
ANS:n C PTS:n n 1
5. Then nursen practitionern (NP)n choosesn ton given cephalexinn everyn 8nhoursn basednonn knowledgenof n t
hen drug’s:
A. Propensityn ton gon ton then target n receptor
B. Biologicaln half-life
C. Pharmacodynamics
D. Safetyn and n siden effects
ANS:n B PTS:n n 1
6. Deferasiroxn isn an chelatingn agent n used ntontreat nironn overload nbynbindingnironn ton rendern it nb
iologicallyn inactive.n Thisn isn best n characterized n asn a(n):
, Woo 2
PharmacotherapeuticsnfornAPNnPrescribers,n6e Ch02
A. Nonreceptorn mechanism
B. Partialn agonist
C. Fulln agonist
D. Noncompetitiven antagonist
ANS:n A PTS:n n 1
7. Then point n inn timen onn thendrugn concentrationn curven that nindicatesn then first n signn ofnantherapeuticn e
ffect n isn the:
A. Minimumn adversen effect n level
B. Peakn of n action
C. Onset n of n action
D. Therapeuticn range
ANS:n C PTS:n n 1
8. Phenytoinn requiresn that n an troughn leveln ben drawn.n Peakn and n troughn levelsn aren done:
A. Whenn then drugn hasn an widen therapeuticn range
B. Whenn then drugn willn ben administered n forn an short n timen only
C. Whenn theren isn an highn correlationn betweenn then dosen and n saturationn of n receptorn sites
D. Ton determinen if n an drugn isn inn then therapeuticn range
ANS:n D PTS:n n 1
9. A n laboratoryn result n indicatesn thatnthenpeaknleveln forn andrugnisn aboventhen minimumn toxicn c
oncentration.n Thisn meansn that n the:
A. Concentrationn willn producen therapeuticn effects.
B. Concentrationn willn producen ann adversen response.
C. Timen betweenn dosesn must n ben shortened.
D. Durationn of n actionn of n then drugn isn toon long.
ANS:n B PTS:n n 1
10. Drugsn that n aren receptorn agonistsn mayn demonstraten what n property?
A. Irreversiblen bindingn ton then drugn receptorn site
B. Up-regulationn withn chronicn use
C. Desensitizationn orn down-regulationn withn continuousn use
D. Inversen relationshipn betweenn drugn concentrationn and n drugn action
ANS:n C PTS:n n 1
11. Drugsn that n aren receptorn antagonists,n suchn asn betan blockers,n mayn cause:
A. Down-regulationn of n then drugn receptor
B. Ann exaggerated n responsen if n abruptlyn discontinued
C. Partialn blockaden of n then effectsn of n agonist n drugs
D. Ann exaggerated n responsen ton competitiven drugn agonists
ANS:n B PTS:n n 1
, Woo 3
PharmacotherapeuticsnfornAPNnPrescribers,n6e Ch02
12. Factorsn that n affect n gastricn drugn absorptionn include:
A. Livern enzymen activity
B. Protein-bindingn propertiesn of n then drugn molecule
C. Lipid n solubilityn of n then drug
D. Abilityn ton chew n and n swallow
ANS:n C PTS:n n 1
13. Drugsn administered n vian IV:
A. Need n ton ben lipid n solublen inn ordern ton ben easilyn absorbed
B. Beginn distributionn inton then bodyn immediately
C. Aren easilyn absorbed n if n theyn aren nonionized
D. Mayn usen pinocytosisn ton ben absorbed
ANS:n B PTS:n n 1
14. Whenn an medicationn isn addedntonanregimenn forn ansynergisticn effect,nthen combined neffectn ofnthend
rugsn is:
A. Then sumn of n then effectsn of n eachn drugn individually
B. Greatern thann then sumn of n then effectsn of n eachn drugn individually
C. Lessn thann then effect n of n eachn drugn individually
D. Not n predictable,n asn it n variesn withn eachn individual
ANS:n B PTS:n n 1
15. Whichn of n then followingn statementsn about n bioavailabilityn isn true?
A. Bioavailabilityn issuesn aren especiallyn important n forn drugsn withn narrow n therapeuticnr
angesn orn sustained-releasen mechanisms.
B. Alln brandsn of n an drugn haven then samen bioavailability.
C. Drugsn that n aren administered n moren thann oncen an dayn haven greatern bioavailabilityn thann
drugsn givenn oncen daily.
D. Combiningn ann activen drugn withn ann inert n substancen doesn not n affect n bioavailability.
ANS:n A PTS:n n 1
16. Whichn of n then followingn statementsn about n then majorn distributionn barriersn (blood–brainn orn fetal–
n placental)n isn true?
A. Watern solublen and n ionized n drugsn crossn thesen barriersn rapidly.
B. Then blood–
brainn barriern slowsn then passagen of n manyn drugsn inton and n out n of n brainn cells.
C. Then fetal–placentaln barriern protectsn then fetusn fromn drugsn takenn byn then mother.
D. Lipid-solublen drugsn don not n passn thesen barriersn and n aren safen forn pregnant n women.
ANS:n B PTS:n n 1
17. Drugsn aren metabolized n mainlyn byn then livern vian phasen Inorn phasenIInreactions.n Then purposen ofn b
othn of n thesen typesn of n reactionsn isn to:
A. Inactivaten prodrugsn beforen theyn cann ben activated n byn target n tissues
n n n n n n n n n n n
Woo 1
Pharmacotherapeutics nfornAPNnPrescribers, n6e Ch01
Chapter n1.nThenRolenofnthenAdvancednPractice nNurse nasnPrescriber
MULTIPLEnCHOICE
1. Nursen practitionern prescriptiven authorityn isn regulated n by:
A. Then Nationaln Counciln of n Staten Boardsn of n Nursing
B. Then U.S.n Drugn Enforcement n Administration
C. Then Staten Board n of n Nursingn forn eachn state
D. Then Staten Board n of n Pharmacy
ANS:n C PTS:n n 1
2. Then benefitsn ton thenpatient nofnhavingn annadvanced npracticen registered n nursen (APRN)n prescribern i
nclude:
A. Nursesn know n moren about n pharmacologyn thannothern prescribersn becausen theyn taken it n
bothn inn theirn basicn nursingn programn and n inn theirn APRN n program.
B. Nursesn caren forn then patient nfromn anholisticn approachn andnincludenthenpatient ninnd
ecision-makingn regardingn theirn care.
C. APRNsn aren lessn likelyn ton prescriben narcoticsn and n othern controlled n substances.
D. APRNsn aren ablen tonprescriben independentlyn inn alln states,n whereasn an physician’sn
assistant n needsn ton haven an physiciann supervisingn theirn practice.
ANS:n B PTS:n n 1
3. Clinicaln judgment n inn prescribingn includes:
A. Factoringn inn then cost n ton then patient n of n then medicationn prescribed
B. Alwaysn prescribingn then newest n medicationn availablen forn then diseasen process
C. Handingn out n drugn samplesn ton poorn patients
D. Prescribingn alln genericn medicationsn ton cut n costs
ANS:n A PTS:n n 1
4. Then processn forn choosingn ann effectiven drugn forn an disordern includes:
A. Askingn then patient n what n drugn theyn thinkn would n workn best n forn them
B. Consultingn nationallyn recognized n guidelinesn forn diseasen management
C. Prescribingn medicationsn that n aren availablen asn samplesn beforen writingn an prescription
D. Followingn U.S.n Drugn Enforcement n Administrationn guidelinesn forn prescribing
ANS:n B PTS:n n 1
5. Nonintentionaln nonadherencen of n drugn therapyn mayn occurn duen to:
A. Belief n that n medicationn doesn not n work
B. Adversen drugn reactions
C. Chronicn conditionsn that n requiren dailyn therapy
D. Forgetfulnessn orn distraction
ANS:n D PTS:n n 1
, Woo 1
PharmacotherapeuticsnfornAPNnPrescribers,n6e Ch02
Chapter n2.nReviewnofnBasic nPrinciples nofnPharmacology
MULTIPLEnCHOICE
1. A n patient’sn nutritionaln intaken andn laboratoryn resultsn reflect n hypoalbuminemia.n Thisn isn criticaln t
on prescribingn because:
A. Distributionn of n drugsn ton target n tissuen mayn ben affected.
B. Then solubilityn of n then drugn willn not n matchn then siten of n absorption.
C. Theren willn ben lessn freen drugn availablen ton generaten ann effect.
D. Drugsn bound n ton albuminn aren readilyn excreted n byn then kidneys.
ANS:n A PTS:n n 1
2. Drugsn that n haven an significant n first-passn effect:
A. Must n ben givenn byn then enteraln (oral)n routen only
B. Bypassn then hepaticn circulation
C. Aren rapidlyn metabolized n byn then livern and n mayn haven little,n if n any,n desired n action
D. Aren converted n byn then livern ton moren activen and n fat-solublen forms
ANS:n C PTS:n n 1
3. Then routen of n excretionn of n an volatilen drugn willn likelyn ben the:
A. Kidneys
B. Lungs
C. Bilen and n feces
D. Skin
ANS:n B PTS:n n 1
4. A n majorn disadvantagen ton IV n administrationn isn that:
A. First-passn metabolismn isn eliminated.
B. Needlesn and n sterilityn aren required.
C. Absorptionn of n then drugn cannot n ben slowed n aftern administration.
D. It n isn significantlyn moren expensiven thann othern routes.
ANS:n C PTS:n n 1
5. Then nursen practitionern (NP)n choosesn ton given cephalexinn everyn 8nhoursn basednonn knowledgenof n t
hen drug’s:
A. Propensityn ton gon ton then target n receptor
B. Biologicaln half-life
C. Pharmacodynamics
D. Safetyn and n siden effects
ANS:n B PTS:n n 1
6. Deferasiroxn isn an chelatingn agent n used ntontreat nironn overload nbynbindingnironn ton rendern it nb
iologicallyn inactive.n Thisn isn best n characterized n asn a(n):
, Woo 2
PharmacotherapeuticsnfornAPNnPrescribers,n6e Ch02
A. Nonreceptorn mechanism
B. Partialn agonist
C. Fulln agonist
D. Noncompetitiven antagonist
ANS:n A PTS:n n 1
7. Then point n inn timen onn thendrugn concentrationn curven that nindicatesn then first n signn ofnantherapeuticn e
ffect n isn the:
A. Minimumn adversen effect n level
B. Peakn of n action
C. Onset n of n action
D. Therapeuticn range
ANS:n C PTS:n n 1
8. Phenytoinn requiresn that n an troughn leveln ben drawn.n Peakn and n troughn levelsn aren done:
A. Whenn then drugn hasn an widen therapeuticn range
B. Whenn then drugn willn ben administered n forn an short n timen only
C. Whenn theren isn an highn correlationn betweenn then dosen and n saturationn of n receptorn sites
D. Ton determinen if n an drugn isn inn then therapeuticn range
ANS:n D PTS:n n 1
9. A n laboratoryn result n indicatesn thatnthenpeaknleveln forn andrugnisn aboventhen minimumn toxicn c
oncentration.n Thisn meansn that n the:
A. Concentrationn willn producen therapeuticn effects.
B. Concentrationn willn producen ann adversen response.
C. Timen betweenn dosesn must n ben shortened.
D. Durationn of n actionn of n then drugn isn toon long.
ANS:n B PTS:n n 1
10. Drugsn that n aren receptorn agonistsn mayn demonstraten what n property?
A. Irreversiblen bindingn ton then drugn receptorn site
B. Up-regulationn withn chronicn use
C. Desensitizationn orn down-regulationn withn continuousn use
D. Inversen relationshipn betweenn drugn concentrationn and n drugn action
ANS:n C PTS:n n 1
11. Drugsn that n aren receptorn antagonists,n suchn asn betan blockers,n mayn cause:
A. Down-regulationn of n then drugn receptor
B. Ann exaggerated n responsen if n abruptlyn discontinued
C. Partialn blockaden of n then effectsn of n agonist n drugs
D. Ann exaggerated n responsen ton competitiven drugn agonists
ANS:n B PTS:n n 1
, Woo 3
PharmacotherapeuticsnfornAPNnPrescribers,n6e Ch02
12. Factorsn that n affect n gastricn drugn absorptionn include:
A. Livern enzymen activity
B. Protein-bindingn propertiesn of n then drugn molecule
C. Lipid n solubilityn of n then drug
D. Abilityn ton chew n and n swallow
ANS:n C PTS:n n 1
13. Drugsn administered n vian IV:
A. Need n ton ben lipid n solublen inn ordern ton ben easilyn absorbed
B. Beginn distributionn inton then bodyn immediately
C. Aren easilyn absorbed n if n theyn aren nonionized
D. Mayn usen pinocytosisn ton ben absorbed
ANS:n B PTS:n n 1
14. Whenn an medicationn isn addedntonanregimenn forn ansynergisticn effect,nthen combined neffectn ofnthend
rugsn is:
A. Then sumn of n then effectsn of n eachn drugn individually
B. Greatern thann then sumn of n then effectsn of n eachn drugn individually
C. Lessn thann then effect n of n eachn drugn individually
D. Not n predictable,n asn it n variesn withn eachn individual
ANS:n B PTS:n n 1
15. Whichn of n then followingn statementsn about n bioavailabilityn isn true?
A. Bioavailabilityn issuesn aren especiallyn important n forn drugsn withn narrow n therapeuticnr
angesn orn sustained-releasen mechanisms.
B. Alln brandsn of n an drugn haven then samen bioavailability.
C. Drugsn that n aren administered n moren thann oncen an dayn haven greatern bioavailabilityn thann
drugsn givenn oncen daily.
D. Combiningn ann activen drugn withn ann inert n substancen doesn not n affect n bioavailability.
ANS:n A PTS:n n 1
16. Whichn of n then followingn statementsn about n then majorn distributionn barriersn (blood–brainn orn fetal–
n placental)n isn true?
A. Watern solublen and n ionized n drugsn crossn thesen barriersn rapidly.
B. Then blood–
brainn barriern slowsn then passagen of n manyn drugsn inton and n out n of n brainn cells.
C. Then fetal–placentaln barriern protectsn then fetusn fromn drugsn takenn byn then mother.
D. Lipid-solublen drugsn don not n passn thesen barriersn and n aren safen forn pregnant n women.
ANS:n B PTS:n n 1
17. Drugsn aren metabolized n mainlyn byn then livern vian phasen Inorn phasenIInreactions.n Then purposen ofn b
othn of n thesen typesn of n reactionsn isn to:
A. Inactivaten prodrugsn beforen theyn cann ben activated n byn target n tissues
